Vedanta Biosciences Confirms Phase 3 RESTORATiVE303 Study of VE303 Will Proceed as Planned Following Interim Analysis Vedanta Biosciences, a late clinical-stage company focused on developing microbiome-based oral therapies for gastrointestinal…
INLEXZO™ (gemcitabine intravesical system) Receives Permanent Billing Code to Enhance Access for Select Bladder Cancer Patients Johnson & Johnson has announced a key reimbursement milestone for its bladder cancer therapy…
FDA Clears Lilly’s Foundayo™ (orforglipron), the First GLP-1 Weight Loss Pill with No Food or Timing Restrictions Eli Lilly and Company has announced a major milestone in the treatment of…
Shape Memory Medical Initiates Patient Enrollment in FLAGSHIP Study of Novel False Lumen Embolization Technology Shape Memory Medical Inc. has announced a major clinical milestone with the enrollment of the…
Agilent Introduces the BioTek Cytation 9 Cell Imaging Multimode Reader Agilent Technologies, Inc. has announced the launch of its latest innovation in laboratory instrumentation, the BioTek Cytation 9 cell imaging…
Janux Therapeutics Confirms Candidate Nomination in Bristol Myers Squibb Partnership, Activating $35 Million Milestone Payment Janux Therapeutics, Inc. has announced a significant milestone under its strategic collaboration with Bristol Myers…
Thermo Fisher Scientific Introduces Unified Platform to Speed Biologics Development Thermo Fisher Scientific Inc., a global leader in scientific services and life sciences solutions, has introduced a next-generation, integrated cell…
RefleXion Achieves Broader Medicare Reimbursement Approval for SCINTIX Cancer Therapy RefleXion Medical has announced a significant advancement in reimbursement support for its innovative SCINTIX® autonomous radiotherapy platform, as Noridian Healthcare…
Gilead Extends Tender Offer Timeline for Planned Acquisition of Arcellx Gilead Sciences, Inc. has announced an extension of its ongoing tender offer to acquire all outstanding shares of common stock…
Alto Neuroscience Shares Topline Results from Phase 2 Proof-of-Concept Trial of ALTO-101 and Highlights Ongoing Pipeline Progress Alto Neuroscience, Inc. has announced topline results from its Phase 2 proof-of-concept (POC)…
FORE Biotherapeutics Earns Breakthrough Therapy Designation for Plixorafenib FORE Biotherapeutics, a registration-stage biopharmaceutical company focused on developing precision therapies for cancer, has announced a significant regulatory milestone for its lead…
Shionogi Secures Complete Ownership of Global Rights to RADICAVA (edaravone) Shionogi & Co., Ltd. has announced the successful completion of a major strategic transaction involving the full transfer of rights…